SL Science (SLBT) Lists on Nasdaq Despite 35% Revenue Drop and Widening Losses... Betting on Cell Therapy

Key takeaway

"SL Science (SLBT) Lists on Nasdaq Despite 35% Revenue Drop and Widening Losses... Betting on Cell Therapy" — BullBear's AI rates this story as a mixed, direction-neutral signal, with a market-impact score of 50 out of 100. Taiwan-based biotech firm SL Science (SLBT) has listed on Nasdaq despite a 35% revenue decline and widening losses, attributed to investments in its cell and gene therapy strategy. The company aims to enter a growth trajectory with new funding, focusing R&D on cell therapy. That score reflects how strongly the story is likely to move Bitcoin, US equities, the dollar, and gold, and near-duplicate coverage of the same event is clustered so only the representative article is scored. BullBear analyzes hundreds of market stories a day this way, turning each into a structured bullish, bearish, or mixed read rather than a raw headline, so the signal can be compared across sources and over time. Reported by TokenPost on June 19, 2026. The bullish and bearish evidence behind this assessment, plus a 24-hour price-move check that verifies the call against what actually happened, are all tracked publicly on BullBear.news.